Trial Profile
Phase II study of first-line WHIT panitumumab and capecitabine in elderly patients with metastatic colorectal cancer and wild type KRAS
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Sep 2017
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Panitumumab (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 27 Sep 2017 Status changed from recruiting to completed.
- 12 Sep 2017 Preliminary results presented at the 42nd European Society for Medical Oncology Congress.
- 06 Jul 2012 New trial record